Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

MenB Vaccine Offers No Gonorrhoea Protection, Major Australian Study Claims

A significant new study has found the Meningitis B vaccine does not protect against gonorrhoea, despite previous hopes. This challenges the basis for its current offering to at-risk men in the UK.

  • A new Australian study found no significant difference in gonorrhoea infections between vaccinated and unvaccinated men.
  • The NHS began offering the MenB vaccine to gay and bisexual men who have sex with men in August 2023, based on earlier research suggesting a protective effect.
  • The UK Health Security Agency (UKHSA) is not making immediate changes, awaiting more robust UK data from its own ongoing studies.
  • Gonorrhoea rates in England reached a peak of 82,592 in 2022 and remain significantly higher than a decade ago.

A major Australian study has thrown into doubt the effectiveness of a vaccine aimed at protecting gay and bisexual men from gonorrhoea, casting uncertainty over the UK's vaccination programme. The trial, named GoGoVax, involved 587 men monitored for two years and revealed that those who received the MenB vaccine had almost identical numbers of new infections – 291 in the vaccinated group compared to 285 in the placebo group.

The research, published in the New England Journal of Medicine, provides "strong evidence" that the MenB vaccine is not effective against gonorrhoea prevention. The findings contradict earlier studies that led to its introduction for at-risk men in the UK and challenge the premise behind the current vaccination programme. NHS sources have indicated that over 30,000 people in England have started the vaccination course, but the UK Health Security Agency (UKHSA) has stated it will not be making any immediate changes to its policy.

Gonorrhoea, a common bacterial infection spread through sexual contact, can lead to symptoms such as pain and unusual discharge. In England, cases reached a peak of 82,592 in 2022, but have since decreased to 63,943 in 2023 – although numbers remain double those reported in 2015. Men who have sex with men continue to be disproportionately affected by the infection.

Experts have described the results as "disappointing", but stress that this should not deter efforts to find an effective vaccine. Gonorrhoea remains a significant global public health threat, particularly due to rising antimicrobial resistance. The Joint Committee on Vaccination and Immunisation (JCVI) has been urged to reconsider its current vaccine programme.

While the MenB vaccine is not effective against gonorrhoea, other preventative measures remain crucial for controlling STIs. Dr Mary Ramsay of the UKHSA noted that ongoing data collection will provide further insight into the vaccine's impact and effectiveness. The Terrence Higgins Trust has called for a review of the current vaccination programme, with its head of health programmes highlighting the importance of condoms and regular testing in preventing and controlling STI transmission.

Why this matters: This study has significant implications for public health strategies in the UK, particularly concerning the prevention of gonorrhoea among at-risk populations. It calls into question the effectiveness of a currently offered vaccine and highlights the ongoing challenge of rising STI rates.

What this means for you: What this means for you: If you are in an at-risk group and have received or are considering the MenB vaccine for gonorrhoea prevention, this study suggests it may not offer the anticipated protection. It reinforces the importance of using condoms and undergoing regular STI testing as primary prevention methods.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.